Abstract:Aim: The objective of this trial is to explore the efficacy and safety of erlotinib (Tarceva ®) as neoadjuvant treatment in stage IIIA-N2 NSCLC patients with activating EGFR mutation. Methods: Previously untreated patients with endobronchial ultrasound confirmed stage IIIA-N2 NSCLC with activating EGFR mutation in exon 19 or 21 were recruited into the study. All enrolled patients were treated with erlotinib 150mg orally per day for 56 days for neoadjuvant period. Only patients who got benefits from erlotinib treatment and were resectable would receive surgery. The primary endpoint is radical resection rate. The secondary endpoints included pathological complete response rate, objective response rate, disease free survival, overall survival, safety profile, and explorative biomarkers. This study was registered in clinicaltrials.gov (NCT01217619). Results: From 10 Oct 2010 to 30 Jun 2014, total 155 patients were screened, 44 patients with IIIA N2, 25 patients (with IIIA N2 EGFR Mutations) were finally enrolled into the study (Table 1). After erlotinib treatment, RR32%, DCR76%. Sixteen patients underwent resection surgery. Fifteen patients (93.8%) had R0 resection and the radical resection rate was 60% (15/25). pCR6.3%; pRR93.7%. The median DFS were 10.4 months. OS data are not mature. All patients were consistent on EGFR mutation before and after the surgery except three patients with exon 19 deletion turn to EGFR wild type after the surgery. Seven patients (28%,7/25) had rash(grade I-II) and one patient had diarrhea(grade I) after erlotinib treatment. Table 1.Tabled 1Patient and disease characteristicsItemsTotal enrolled (n = 25)No surgery (n = 9)Surgery (n = 16)Age, median (range), year59 (33,74)59 (33,74)60 (38,73)Sex,male/female13/127/26/10ECOG, n (%)125 (100%)9 (100%)16 (100%)Current or former smoker/never-smoker12/137/25/11EGFR mutation type before erlotinib, n(%)exon 19 deletion16 (64%)6 (66.7%)10 (62.5%)exon 21 L858R mutation10 (40%)4 (44.4%)*one patient had both exon 19 deletion and exon 21 L858R point mutation.6 (37.5%)Carcinoembryonic antigen, µg/L, mean (S.D.)Before treatment78.2 (140.6)120.8 (185.9)54.2 (99.2)4 weeks after erlotinib41.7 (86.7)89.7 (124.0)12.2 (19.9)7 weeks after erlotinib33.2 (61.9)106.8 (92.4)10.6 (14.5)after surgeryNANA3.2 (2.2)AE during erlotinib treatment, n(%)Rash7 (28%)2 (22.2%)5, (31.3%)Diarrhea1 (4%)01 (6.3%)Abnormal liver function1 (4%)1 (11.1%)0Leukocytopenia1 (4%)1 (11.1%)0Cerebral infarction1 (4%)1 (11.1%)0Reason for no surgeryProgress of disease6NASerious AE (cerebral infarction)1NANot suitable for surgery2NA* one patient had both exon 19 deletion and exon 21 L858R point mutation. Open table in a new tab Conclusions: Erlotinibas neoadjuvant therapyis a promising treatment for EGFR mutant IIIA-N2 NSCLC patients with tolerable toxicity. Clinical trial identification: (NCT01217619, ESTERN) 10-2010 Disclosure: All authors have declared no conflicts of interest.

Osimertinib As Neoadjuvant Therapy in Patients with EGFR-mutant Resectable Stage II-IIIB Lung Adenocarcinoma (NEOS): A Multicenter, Single-Arm, Open-Label Phase 2b Trial.

Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS).

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series

A new, potential and safe neoadjuvant therapy strategy in epidermal growth factor receptor mutation-positive resectable non-small-cell lung cancer-targeted therapy: a retrospective study

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

Camrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Oesophageal Squamous Cell Carcinoma: a Single-Arm Phase 2 Trial

AUTOMAN: A phase Ib/IIa study of osimertinib combined with anlotinib in EGFRm, treatment-naive advanced NSCLC patients

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC

Analysis of the Clinical Effect of Osimertinib on 90 Cases with Advanced Lung Adenocarcinoma

A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy

Erlotinib As Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study

Erlotinib As Neoadjuvant Treatment in Patients with Iiia-N2 Non-Small Cell Lung Cancer(Nsclc) with Activating Epidermal Growth Factor Receptor (egfr) Mutation (nct01217619, Estern)

Phase Ib/IIa Study Evaluating the Safety and Clinical Activity of Osimeritinib Combined with Anlotinib in EGFRm, Treatment-Naive Advanced NSCLC Patients (AUTOMAN).

Erlotinib As Neoadjuvant Treatment in Endobronchial Ultrasound Confirmed Stage IIIA-N2 Non-Small Cell Lung Cancer (NSCLC) Patients with Epidermal Growth Factor Receptor (EGFR) Mutation (EXON 19 OR 21) (NCT01217619, ESTERN): a Prospective, Single Arm, Phase Ii Clinical Trial

Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLC

Adjuvant Osimertinib in Patients with Stage IB to IIIA EGFR Mutation-Positive NSCLC after Complete Tumor Resection: ADAURA China Subgroup Analysis

Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study

Neoadjuvant Toripalimab Plus Chemotherapy for Resectable Stage II-IIIB Non-Squamous Non-Small Cell Lung Cancer with EGFR Mutations: A Multi-Center, Multi-Cohort, Exploratory Study.